Treos Bio Announces $ 14 Million Convertible Loan Funding to Advance Computer-Designed Peptide Cancer Immunotherapies Platform
Product to Fund Phase II Clinical Trials of PolyPEPI-1018, the Company’s Ready-to-Use Polypeptide Immunotherapy for Metastatic Colorectal Cancer
Funding was led by Luminous Ventures and the UK Government’s Future Fund
Isabel Fox, Co-Managing Partner at Luminous Ventures, joins Treos Board of Directors
LONDON, March 31, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical-stage biotechnology company using data science and proprietary biomarkers to develop precise and personalized peptide immunotherapies against cancer, announced today it closed a $ 14 million convertible loan note financing. The funding was led by Luminous Ventures and the UK government’s Future Fund, both first-time investors in Treos. In addition, Isabel Fox, Associate Co-Manager of Luminous Ventures, has joined the Treos Board of Directors.
The product will fund the phase II clinical trials of lead candidate PolyPEPI-1018, the Company’s ready-to-use experimental precision immunotherapy for the treatment of patients with stable microsatellite metastatic colorectal cancer (MSS mCRC). In a previous Phase I / II study in patients with MSS mCRC, PolyPEPI-1018 was shown to induce robust antigen-specific T cell responses and long-lasting anti-tumor responses.
“We are delighted to invest in Treos and support the clinical development of the company’s new cancer immunotherapy technology, which applies proprietary data science to numerically match antigens expressed by a specific cancer to the genetics of each. patient, ”said Isabel Fox, Co. – Managing Partner at Luminous Ventures. “Using new biomarkers, scientists at Treos have created an exciting platform to develop polypeptide immunotherapies that can potentially result in clinical benefit for patients with many types of hard-to-treat solid tumors. “
“We are delighted to welcome Isabel to the Treos Board of Directors and we are proud to partner with Luminous Ventures and the UK Government’s Future Fund as their support allows us to continue to refine our proprietary IT platform and to advance our precision immunotherapy technology in the treatment of cancer, ”said Dr. Christopher C. Gallen, MD, Ph.D., CEO of Treos. “Following this inflection point, we look forward to the launch of two clinical trials over the next six months evaluating PolyPEPI-1018 as an addition to first-line maintenance therapy and third-line therapy in patients. with MSS mCRC. “
About Treos Bio Limited
Treos Bio uses computational data science and proprietary biomarkers to develop precise and personalized peptide immunotherapies against cancer. The Company has developed a unique ability to match antigens expressed by a specific cancer to the target recognition mechanism of the individual patient. This technology aims to meet the challenge of the variability of the clinical responses of each patient to cancer immunotherapies. Treos’ lead candidate is PolyPEPI-1018, a ready-to-use immunotherapy for the treatment of metastatic colorectal cancer, co-developed with a companion diagnostic candidate. Treos is developing personalized immunotherapies for several types of solid tumors and has completed the preclinical development of ready-to-use PolyPEPI immunotherapies in ovarian, breast, bladder, stomach and lung cancers and melanoma. The Company is also developing an experimental COVID-19 peptide vaccine, PolyPEPI-SCoV-2. Treos launched in February 2017 and has raised $ 28 million in Series A financing led by BXR Group shareholders. More information can be found at www.treosbio.com.
About Luminous Ventures
Luminous Ventures is a London-based venture capital fund that invests in cutting-edge technology with a focus on the application of artificial intelligence, virtual reality, augmented reality, advanced computing , from robotics, quantum technologies and synthetic biology to healthcare, life sciences, nutrition and food in Europe. and North America.
About the UK Government’s Future Fund
The UK Government’s Future Fund was established to support innovative UK businesses currently affected by Covid-19. These companies have not been able to access other public business support programs, such as CBILS, as they are either pre-income or pre-profit and generally depend on equity investments. The Future Fund, now closed to new applications, offers qualifying companies convertible loans, provided private investors at least match the government’s commitment. Convertible loans are designed to be converted into equity in the next qualifying round of financing. The Future Fund is developed by the government and issued by the British Business Bank.